Please assess the completion status of the following clinical trial:

Trial Title: The NOR-SWITCH Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A clinical diagnosis of either rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease or chronic plaque psoriasis~2. Male or non-pregnant, non-nursing female~3. \>18 years of age at screening~4. Stable treatment with innovator infliximab (Remicade) during the last 6 months~5. Subject capable of understanding and signing an informed consent form~6. Provision of written informed consent~Exclusion Criteria:~1. Major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4) and/or severe respiratory diseases~2. Change of major co-medication during the last 2 months prior to randomization:~   RA, SpA and PsA: Initiation of systemic corticosteroids or synthetic DMARDs or other medication which according to the investigator would interfere with the stability of the disease.~   UC and CD: Initiation of systemic corticosteroids or an immunosuppressant or other medication which according to the investigator would interfere with the stability of the disease Psoriasis: Initiation of synthetic DMARDs or other medication which according to the investigator would interfere with the stability of the disease~3. Inadequate birth control, pregnancy, and/or breastfeeding~4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible~5. Change in treatment with innovator infliximab (Remicade) during the last 6 months due to disease related factors, not including dose/frequency adjustments due to drug concentration measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: EXPERIMENTAL): Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
- INX (Type: ACTIVE_COMPARATOR): Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion

Based on this trial design, predict the completion outcome and termination type (if applicable).